Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease

INTRODUCTION: Donanemab is an amyloid‐targeting therapy that specifically targets brain amyloid plaques. The objective of these analyses was to characterize the relationship of donanemab exposure with plasma biomarkers and clinical efficacy through modeling. METHODS: Data for the analyses were from...

Descripción completa

Detalles Bibliográficos
Autores principales: Gueorguieva, Ivelina, Willis, Brian A., Chua, Laiyi, Chow, Kay, Ernest, C. Steven, Wang, Jian, Shcherbinin, Sergey, Sims, John R., Chigutsa, Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301702/
https://www.ncbi.nlm.nih.gov/pubmed/37388759
http://dx.doi.org/10.1002/trc2.12404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301702/
https://www.ncbi.nlm.nih.gov/pubmed/37388759
http://dx.doi.org/10.1002/trc2.12404

Ejemplares similares